THE DATA OF DNA- FLOW CYTOMETRY IN PROGNOSIS OF CERVIX CANCER


Cite item

Full Text

Abstract

The purpose of research - the study of quantitative cell cervical cancer (CC) due to radiation therapy: ploidy and their distribution over the phases of the cell cycle analysis of the relationship of these parameters with clinical prognosis factors. Presents the group of 121 patients with CC II, III, IV stages, where the courses combined radiotherapy were from 2000 to 2008. Biopsy tumor samples were used during the radiotherapy. Diploid tumors were detected in 38 (31.4%) patients, aneuploid - in 75 (62%), tetraploid - in 7 (5.8%) and 1 (0.8%) - gyperaneuploid tumor. Overall and disease free-5-year survival in diploid tumors was higher (68,4 ± 9,6% and 45,1 ± 11,0%) compared to the aneuploid (45,4 ± 8,4% and 32.7 ± 7,2%), p <0.05. Among aneuploid CC recurrence rate is higher than the diploid: 24.0% versus 2.6% (p <0.05), respectively. Aneuploid CC with S phase fraction <7% associated with better overall and disease-free survival within 5 years was 57,2 ± 13,1% and 45,6 ± 11,3%, than those with S-phase fraction 7%- > 14 % - 32,3 ± 10,3% and 18,2 ± 8,5% (p = 0.03 and p = 0.0006), respectively. For S-phase fraction ≥ 14% of all patients died within the 1st year follow-up of disease progression. Similarly, in a group of diploid tumors disease free-5-year survival (p = 0.002) with a low content of cells in S phase was 74,7 ± 10,1% of patients. When S-phase fraction > 7%, all patients died within 3 years of the progression of the disease. With increasing stage of cervical cancer, increased proliferative activity of aneuploid tumors. Disease-free survival was worse with increasing PI (p = 0.01). In patients with cervical cancer stage III - IV at age <49 years, the main prognostic factors include poor differentiated squamous cancer, PI of 15 to 20%, IDNA within 1.1 - 1.84 and more. In patients > 49 years - PI over 20% and IDNA 0.6 - 0.8. In this category of patients the course of chemo-radiotherapy is appropriate. Both ploidy and number of cells in S phase should be seen as independent prognostic criteria in patients with stage II CC.

About the authors

O. A Kravets

N.N.Blokhin Russian Cancer Research Center of the Russian Academy of Medical Sciences,

Email: kravetz_olga@mail.ru
д-р мед наук, ст. науч. сотр. отд-ния радиохирургии

V. N Bogatyrev

N.N.Blokhin Russian Cancer Research Center of the Russian Academy of Medical Sciences,

ведущий научный сотрудник, доктор медицинских наук, профессор.

References

  1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2009 г. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2011; 22 (3): прил. 1.
  2. Bogatyrev V.N., Grigoruk O.G., Lazarev A.F., Bazulina L.M. Potentialities of cytological method in diagnostics of HPV-infection of cervix uteri based on cytological screening. 34-th European congress of cytology, 15-18 June 2008, Rovaniemi, Finland. Cytopathology. 2008; 19 (Suppl. 1): 91.
  3. Бохман Я.В. Руководство по онкогинекологии. Л.: Медицина; 1989.
  4. Косенко И.А., Мириленко Л.В. Прогностические критерии результатов лечения неоперабельных больных раком шейки матки. В кн.: Клиническая онкология: Сборник науч. работ. Минск; 1999: 175-80.
  5. Chen R.J. Influence of gystologic type and age on survival rates for invasive cervical carcinoma in Taiwan. Academic Press USA. 1999; 73 (2): 184-90.
  6. Chen S.W., Liang J.A., Yang S.N. et al. The adverse effect of treatment prolongation in cervical cancer by high-dose-rate intracavitary brachytherapy. Radiother. Oncol. 2003; 67 (1): 69-76.
  7. Kubicky C.D., Yeh B.M., Lessard E. et al. Inverse planning simulated annealing for magnetic resonance imaging-based intracavitary high-dose-rate brachytherapy for cervical cancer. Brachytherapy. 2008; 7 (3): 242-7.
  8. Mazeron J.J., Scalliet P., Van Limbergen E. et al. Radiobiology of brachytherapy and the dose-rate effect. In: Gerbaulet A., Potter R., Mazeron J-J., Meertens H., Limbergen E. V., eds. The GEC-ESTRO handbook of brachytherapy. Brussels: ESTRO; 2002: P. 95-121.
  9. Nag S., Erickson B., Thomadsen B. et al. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix. Int. J. Radiat. Oncol. Biol. Phys. 2000; 48 (1): 201-11.
  10. Меньшиков В.В., ред. Клиническая лабораторная аналитика. Т. 2: Частные аналитические технологии в клинической лаборатории. М.: Лабинформ-РАМЛД; 1999.
  11. Susini T., Olivieri S., Molino C. et al. DNA ploidy is stronger than lymph node metastasis as prognostic factor in cervical cancer: 10-years results of a prospective study. Int. J. Gynecol. Cancer. 2011; 21 (4): 678-84.
  12. Pinto A.E., Pires A., Silva G. et al. Ploidy and S-phase fraction as predictive markers of response to rediotherapy in cervical cancer. Pathol. Res. Pract. 2011; 207 (10): 623-27.
  13. Chhavi, Saxena M., Negi M.P., Singh S. et al. DNA content can improve the detection and prognosis of carcinoma of the cervix. Biosci. Trends. 2010; 4 (3): 103-9.
  14. Kallioniemi O.P. Comparison of fresh and paraffin-embedded tissue as a starting material for DNA-flow cytometry and evaluation of intratumor heterogeneity. Cytometry. 1988; 9 (2): 164-9.
  15. Chen C.A., Wu C.C., Chen T.M. et al. Cell kinetics and radiosensitivity of cervical squamous cell carcinoma. Cancer Lett. 1994; 82 (2): 135-40.
  16. Konski A., Domenico D., Irving D. et al. Flow cytometric DNA content analysis of paraffin-embedded tissue derived from cervical carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 1994; 30 (4): 839-43.
  17. Swyngedaw J. System T.D.F. (Temps-Dose-Fractionnement) et tolerance vis-a-vis irradiations a faible debit et faible fractionnement. J. Radiol. Electrol. 1985; 57 (5): 373-7.

Copyright (c) 2013 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies